

Meta-Analysis

Neurosurg Rev. 2024 Sep 14;47(1):613. doi: 10.1007/s10143-024-02858-3.

# Letter to Editor, "The effects of dabrafenib and/or trametinib treatment in Braf V600mutant glioma: a systematic review and metaanalysis"

Hethesh Chellapandian <sup>1</sup>, Sivakamavalli Jeyachandran <sup>2</sup>

Affiliations

PMID: 39271502 DOI: [10.1007/s10143-024-02858-3](https://doi.org/10.1007/s10143-024-02858-3)

## Abstract

This systematic review and meta-analysis evaluates the effects of dabrafenib and/or trametinib in treating BRAF V600-mutant gliomas. The study analyzed eight trials involving both high-grade and low-grade glioma patients, assessing outcomes such as progression-free survival (PFS), overall survival (OS), adverse events (AEs), and disease response. The pooled results showed a median PFS of 6.10 months and OS of 22.73 months, with notable improvement in disease response rates when using combination therapy. However, the high incidence of AEs (50%) and death events (43%) necessitates caution in interpreting these results. The study's limitations include a lack of randomized controlled trials and high heterogeneity in AE data. Future research should focus on larger, controlled studies, standardized AE assessments, and exploration of neurocognitive outcomes to better understand and optimize treatment strategies for BRAF V600-mutant gliomas.

**Keywords:** BRAF V600-mutant glioma; Dabrafenib; Meta-analysis; Targeted therapy; Trametinib.

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

[PubMed Disclaimer](#)